Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, 2300 I St NW, 20037, Washington, DC, USA.
Asian J Psychiatr. 2019 Feb;40:100-102. doi: 10.1016/j.ajp.2019.02.007. Epub 2019 Feb 12.
Preclinical evidence shows that the minocycline and N-acetylcysteine (NAC) combination synergistically improved cognition. Meta-analyses of randomized controlled trials (RCTs) with minocycline and NAC have shown some efficacy signal for positive, cognitive, and negative symptoms of schizophrenia. Hence, the combination may be more effective than either medication alone. The objective of this article is to highlight the potential role of the minocycline-NAC combination for the treatment of schizophrenia. The antipsychotic-minocycline-NAC combination is promising and has the potential to concurrently treat positive, cognitive, and primary negative symptoms. RCTs are warranted with the minocycline-NAC combination to address the unmet clinical need in schizophrenia.
临床前证据表明，米诺环素和 N-乙酰半胱氨酸 (NAC) 的联合使用具有协同作用，可以改善认知功能。对米诺环素和 NAC 的随机对照试验 (RCT) 的荟萃分析显示，该联合用药对精神分裂症的阳性、认知和阴性症状有一定的疗效信号。因此，该联合用药可能比单独使用任何一种药物更有效。本文的目的是强调米诺环素-NAC 联合用药治疗精神分裂症的潜在作用。抗精神病药物-米诺环素-NAC 联合用药具有广阔的前景，有可能同时治疗阳性、认知和原发性阴性症状。需要进行米诺环素-NAC 联合用药的 RCT，以满足精神分裂症领域的未满足的临床需求。
